AstraZeneca's Dafni Bika Reframes Sustainability in Pharma at MAST Showcase

“Sustainability” used to be called value engineering.

That was one of the more important reframes from AstraZeneca’s Dafni Bika at the 2026 MAST Showcase — because it cuts through the idea that sustainability in pharma is separate from operations, manufacturing, or business performance.

It isn’t.

At AstraZeneca, sustainability metrics now touch molecule design, supplier contracts, AI infrastructure, logistics, executive compensation, and manufacturing strategy.

And the numbers reveal why this has become operationally urgent:

• Pharma accounts for ~5% of global emissions
• Roughly half of AstraZeneca’s footprint comes from inhaler propellants
• Scope 1 & 2 emissions? Only ~2% of the total footprint
• The hardest work sits in Scope 3 — suppliers, materials, packaging, and external systems

What stood out most was the shift from aspiration to accountability.

Supplier requirements are now embedded into contracts. Executive bonuses are tied to sustainability targets. AI infrastructure decisions consider energy footprints. And decarbonizing inhalers required years of redevelopment and hundreds of millions in investment.

The bigger signal: sustainability is no longer a side initiative in life sciences. It is becoming a systems-level business discipline.

For engineers, operators, and biotech leaders, the takeaway may be simpler than the terminology suggests:

The instinct behind good sustainability is the same instinct behind good engineering — reduce waste, optimize systems, and design problems out before they scale.

Read the full BioBuzz recap here:
#Biotech #LifeSciences #Sustainability #Manufacturing #Pharma #AI #BioBuzz #MASTShowcase #ISPE #AstraZeneca